Sumatriptan succinate transdermal delivery systems for the treatment of migraine

Authors

  • C. Balaguer-Fernández,

    1. Departamento de Fisiología, Farmacología y Toxicología, Facultad de Ciencias Experimentales y de la Salud, Universidad CEU Cardenal Herrera, 46113 Moncada, Spain
    Search for more papers by this author
  • A. Femenía-Font,

    1. Departamento de Fisiología, Farmacología y Toxicología, Facultad de Ciencias Experimentales y de la Salud, Universidad CEU Cardenal Herrera, 46113 Moncada, Spain
    Search for more papers by this author
  • S. del Rio-Sancho,

    1. Departamento de Fisiología, Farmacología y Toxicología, Facultad de Ciencias Experimentales y de la Salud, Universidad CEU Cardenal Herrera, 46113 Moncada, Spain
    Search for more papers by this author
  • V. Merino,

    1. Departament de Farmàcia i Tecnologia Farmacèutica, Facultat de Farmàcia, Universitat de València, 46100 Burjassot, Spain
    Search for more papers by this author
  • A. López-Castellano

    Corresponding author
    1. Departamento de Fisiología, Farmacología y Toxicología, Facultad de Ciencias Experimentales y de la Salud, Universidad CEU Cardenal Herrera, 46113 Moncada, Spain
    • Departamento de Fisiología, Farmacología y Toxicología, Facultad de Ciencias Experimentales y de la Salud, Universidad CEU Cardenal Herrera, 46113 Moncada, Spain. Telephone: 34-961369000-1139, Fax: 34-961395272.
    Search for more papers by this author

Abstract

We have successfully obtained sumatriptan transdermal systems with different polymer compositions: methyl cellulose (MC), polyvinyl pyrrolidone (PVP) and a polyvinyl pyrrolidone (PVP)-polyvinyl alcohol (PVA) mixture. The systems contained 1,2-propilenglycol (MC) or sorbitol as a plasticizer (PVP and PVP-PVA), methacrylate copolymer as an adhesive agent, and an occlusive liner. Azone® (5%, w/w) was incorporated into all the systems as a percutaneous enhancer. Transdermal systems are thin, transparent and non-adhesive when in a dry state. The permeation of sumatriptan succinate across pig ear skin was studied using the systems prepared. The formulation with MC polymer produced a statistically significant increment with respect to the PVP and PVP-PVA formulations (p < 0.05). Azone® incorporation into the systems produced an increment in the sumatriptan flux values of all three transdermal systems with respect to those of the controls (p < 0.05). In addition, the application of iontophoresis to the wet methyl cellulose-Azone® formulation produced a much higher increase of sumatriptan transdermal flux. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:2102–2109, 2008

Ancillary